Enhanced CD33+CD11b+HLA-DR–CD14–CD66b+ and CD33+CD11b+HLA-DR–CD14+CD66b– cells in the blood of ICU patients, classified as severe COVID patients, could represent not only a predictor of prognosis for COVID-19, but also specific therapy targets for treating this virus infection in the near future. The gene discussed is CD33; the disease is COVID-19.